Literature DB >> 22674947

Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions.

Tiago Moreira1, Lotfi Khemiri, Lennart Runeson.   

Abstract

A 45-year-old man with bipolar disease type I and post-traumatic frontal lobe lesions following a previous psychotic episode was hospitalised after having stopped taking aripiprazole (15 mg/day) and lithium (126 mg twice/daily). He presented with hypomania, psychosis, verbal unresponsiveness and disorientation. He engaged in compulsive onanism in public which resulted in the restriction of his freedom, suggesting impulse control disorder (ICD). Electroencephalogram showed no epileptiform activity. Brain CT-scan showed post-traumatic bifrontal and left occipital lesions. Viral and bacterial serologies were normal. Lithium was initially reinstated (same dose), but it was aripiprazole reinstatement at a lower dose (10 mg) that made his condition rapidly improve within 24-36 h. Aripiprazole is a partial dopamine D2-receptor antagonist that blocks dopamine at higher dopamine concentrations and augments/releases prefrontal cortex dopamine at lower concentrations. The rapid recovery suggests stabilisation of dopamine levels in the frontal lobes and that ICD may be modified by aripiprazole treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22674947      PMCID: PMC3229334          DOI: 10.1136/bcr.09.2011.4756

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective.

Authors:  Antoine Bechara
Journal:  Nat Neurosci       Date:  2005-11       Impact factor: 24.884

Review 2.  Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia.

Authors:  Christos Pantelis; Murat Yücel; Stephen J Wood; Dennis Velakoulis; Daqiang Sun; Gregor Berger; Geoff W Stuart; Alison Yung; Lisa Phillips; Patrick D McGorry
Journal:  Schizophr Bull       Date:  2005-07-14       Impact factor: 9.306

Review 3.  The neurobiology and genetics of impulse control disorders: relationships to drug addictions.

Authors:  Judson A Brewer; Marc N Potenza
Journal:  Biochem Pharmacol       Date:  2007-07-03       Impact factor: 5.858

Review 4.  Cerebral blood flow, metabolic, receptor, and transporter changes in bipolar disorder: the role of PET and SPECT studies.

Authors:  Ali Saffet Gonul; Kerry Coburn; Mustafa Kula
Journal:  Int Rev Psychiatry       Date:  2009

5.  A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

Authors:  Paul E Keck; Joseph R Calabrese; Robert D McQuade; William H Carson; Berit X Carlson; Linda M Rollin; Ronald N Marcus; Raymond Sanchez
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 6.  [Psychopathology of stroke].

Authors:  Antonio Carota; Sebastian Dieguez; Julien Bogousslavsky
Journal:  Psychol Neuropsychiatr Vieil       Date:  2005-12

7.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Authors:  Stephen R Marder; Robert D McQuade; Elyse Stock; Stephen Kaplita; Ronald Marcus; Allan Z Safferman; Anutosh Saha; Mirza Ali; Taro Iwamoto
Journal:  Schizophr Res       Date:  2003-06-01       Impact factor: 4.939

8.  Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.

Authors:  Konstantin Voronin; Patrick Randall; Hugh Myrick; Raymond Anton
Journal:  Alcohol Clin Exp Res       Date:  2008-09-08       Impact factor: 3.455

9.  Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism.

Authors:  Andreas Fellgiebel; Matthias J Müller; Christoph Hiemke; Peter Bartenstein; Matthias Schreckenberger
Journal:  World J Biol Psychiatry       Date:  2007       Impact factor: 4.132

Review 10.  Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.

Authors:  Anthony DeLeon; Nick C Patel; M Lynn Crismon
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.